Walvax Biotechnology Co., Ltd.

300142

CNE100000WN2

Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.

Sector

Pharmaceuticals

Calendar

2024-04-19 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Walvax Biotechnology Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

14.22 CNY

Average target price

21 CNY

Spread / Average Target

+47.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
WALVAX BIOTECHNOLOGY CO., LTD.	-39.52%	3.14B
CSL LIMITED	-4.17%	86.99B
SAMSUNG BIOLOGICS CO.,LTD.	+4.34%	40.68B
BIOGEN INC.	-24.19%	28.61B
UCB	+51.27%	24.1B
BIOMARIN PHARMACEUTICAL INC.	-5.00%	17.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.11%	13.72B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-5.10%	12.49B
INCYTE CORPORATION	-14.52%	12B
SWEDISH ORPHAN BIOVITRUM AB	-3.22%	7.94B

Biopharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-14 pm EDT			5-day change	1st Jan Change
14.22 ^CNY	-1.46%		-5.26%	-39.52%

Apr. 02	Walvax Biotechnology's 2023 Profit Falls 42%	MT
Apr. 01	Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023	CI

Walvax Biotechnology's 2023 Profit Falls 42%	Apr. 02	MT
Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023	Apr. 01	CI
Walvax Biotechnology Scraps Plan to Issue Convertible Bonds	Apr. 01	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit	Jan. 26	MT
Chinese Shares End Mixed as Stimulus Hopes Fade; Walvax Falls 6% on Downbeat Profit Outlook	Jan. 26	MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China	Jan. 10	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	Jan. 03	CI
Lanvin Group Chief Executive Joann Cheng Steps Down	Dec. 08	MT
Walvax Biotechnology Registers Pneumonia Vaccines in Philippines	Nov. 08	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3%	23-10-24	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	23-10-11	CI
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia	23-09-20	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Walvax Biotechnology's COVID-19 Vaccine Clinical Trial Results Show Efficacy, Safety	23-07-11	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	23-07-03	CI
Walvax Biotechnology Chairman, Affiliates Complete Purchase of 101 Million Yuan Shares	23-06-26	MT
Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023	23-05-05	CI
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2022	23-04-21	CI
Walvax Biotechnology Co., Ltd. announces an Equity Buyback for 4,000,000 shares, for CNY 200 million.	23-04-05	CI
Walvax Biotechnology Co., Ltd. authorizes a Buyback Plan.	23-04-03	CI
Walvax Biotechnology Co., Ltd. Proposes Cash Dividend for 2022	23-03-30	CI
Walvax Biotechnology Gets Patent for Freeze-Drying System for Vaccines	23-02-27	MT